Nasdaq rxrx

In the previous quarter, Recursion Pharmaceutic

Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance.Recursion Pharmaceuticals (NASDAQ: RXRX) leverages AI and machine learning to revolutionize the discovery of drug candidates. They analyze vast amounts of biological and imaging data from assays, ...Recursion Pharmaceuticals (RXRX) Stock Forecast & Price TargetStrong Buy 3 Ratings 3 Buy 0 Hold 0 Sell Based on 3 analysts giving stock ratings to Recursion Pharmaceuticals in the past 3 months RXRX Stock 12 Months Forecast $48.67 (32.67% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Recursion Pharmaceuticals in …

Did you know?

The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by TD Cowen on Friday, January 26, 2024.The analyst firm set a price target for 0.00 expecting RXRX to fall to ...Fintel reports that on May 9, 2023, Needham reiterated coverage of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 206.61% Upside. As of ...Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company’s equity securities).About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...The budgetary allocation to AI and machine learning in healthcare is expected to reach 10.5% in 2024, up from 5.5% in 2022, Morgan Stanley says. Read more here.Find the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share (EPS) of ($0.43). Learn more on analysts' earnings estimate vs. RXRX's actual earnings. Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...SALT LAKE CITY, Dec. 6, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery ...Recursion Pharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View RXRX financial statements in full.NVIDIA Corporation Common Stock. $450.47 +0.42 +0.09%. MSFT. Microsoft Corporation Common Stock. $352.60 -0.20 -0.06%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Recursion Pharmaceuticals Stock Down 2.6 %. Shares of NASDAQ RXRX opened at $9.63 on Monday. The business has a 50-day simple moving average of $8.96 and a two-hundred day simple moving average of ...Dec 14, 2023 · Clinical-stage biotech companies often take time to be profitable. Recursion's total revenue in Q3 dipped to $10.5 million compared to $13.2 million in Q3 2022. Its net loss in the quarter came in ... Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Jan 19, 2024 · Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements.

Recursion Pharmaceuticals: More Hype Than Substance (NASDAQ:RXRX) | Seeking Alpha Join the community. Try Seeking Alpha for free by creating an account» …Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company that is involved in decoding biology and screening drugs to arrange them in a way that can aid the efficient ...Feb 28, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago. 3. Its services segment has yet to prove its value. Recursion has three segments: Its pipeline, discovery collaborations, and software licensing. Its pipeline projects are still early-stage, so ...

Shares of NASDAQ:RXRX opened at $10.23 on Friday. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.54 and a 52 week high of $16.75. The firm’s 50 day moving average is $9.27 and its two ...(NASDAQ: RXRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 9.91%. What is RXRX's Price Target? According to 5 Wall Street analyst s that have issued a 1 year RXRX price target, the average RXRX price target is $16.80 , with the highest RXRX stock price forecast at $33.00 and the lowest RXRX stock price …Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Get the latest Recursion Pharmaceuticals In. Possible cause: Recursion Pharma (NASDAQ: RXRX) made waves this week.On Wednesday, the .

Dec 14, 2023 · Clinical-stage biotech companies often take time to be profitable. Recursion's total revenue in Q3 dipped to $10.5 million compared to $13.2 million in Q3 2022. Its net loss in the quarter came in ... (NASDAQ: RXRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 9.91%. What is RXRX's Price Target? According to 5 Wall Street analyst s that have issued a 1 year RXRX price target, the average RXRX price target is $16.80 , with the highest RXRX stock price forecast at $33.00 and the lowest RXRX stock price …RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. Market closed Market closed. No trades. See on Supercharts. Overview Financials . News . Ideas Technicals Forecast . RXRX news flow. News didn't load. Looks like that didn't go very well. Let's try again.

Recursion Pharmaceuticals (NASDAQ: RXRX) exploded in July on the strength of hot news—a $50 million direct investment from Nvidia (NASDAQ: NVDA). Since that month’s high, shares are back in ...Jan 2, 2024 · But Recursion Pharmaceuticals (NASDAQ: RXRX) is accelerating drug discovery using artificial intelligence . This novel approach makes RXRX a top biotech stock to capture the broad longevity trend.

Recursion Pharmaceuticals (NASDAQ: RXRX) is one of the Welcome to Recursion: The Future of TechBio LEARN HOW › NEWS: Recursion unveils LOWE, an LLM-Orchestrated Workflow Engine for drug discovery Decoding Biology To … Stocks RXRX Recursion Pharmaceuticals Stock (NAThe stock price for . Recursion Pharmaceuticals (NASDAQ: NASDAQ:RXRX opened at $9.78 on Friday. Recursion Pharmaceuticals has a 1 year low of $4.54 and a 1 year high of $16.75. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -6 ... Fintel reports that on April 18, 2023, Needham reiterated coverage SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. RXRX Latest Real Time Trades ... Add symbols now or seRecursion Pharmaceuticals Insider Sold Shares Worth $117,180, AccoKey statistics. On Friday, Recursion Pharma 4. Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best and most notable AI healthcare stocks to buy. The Utah-based Recursion ...2 days ago · Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing. The transaction was executed at ... Jan 4, 2024 · Recursion (NASDAQ: RXRX) is a cl Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist Add to Portfolio RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS … So should Recursion Pharmaceuticals (NASDAQ:RXRX) shareholders be [Recursion Pharmaceuticals (RXRX) came out with a quStock. Equities. Stock Recursion Pharmaceuticals, Inc. - Nasda Recursion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RXRX updated stock price target summary.